Cytochrome P450-based cancer gene therapy: current status
- 1 December 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 2 (8), 857-868
- https://doi.org/10.1517/14712598.2.8.857
Abstract
Results from a number of preclinical studies have demonstrated that a P450-based gene-directed enzyme prodrug therapy (GDEPT) strategy for the treatment of cancer is both safe and efficacious. This strategy has now moved forward into the clinic. At least two different approaches using different delivery methods (retroviral vector MetXia [Oxford BioMedica] and encapsulated P450 expressing cells), different cytochrome P450 isoforms (human CYP2B6 versus rat CYP2B1) and different prodrugs (cyclophosphamide [CPA] versus ifosfamide [IFA]) have concluded Phase I/II clinical trial with encouraging results. In the future, P450-based GDEPT can potentially be further enhanced by improved vectors for P450 gene delivery and disease-targeted promoters for focused gene expression at the target site. In addition, there is scope for developing synthetic P450s and their respective prodrugs to improve both enzyme kinetics and the profile of the active moiety.Keywords
This publication has 35 references indexed in Scilit:
- New agents for the treatment of renal cell carcinomaExpert Review of Anticancer Therapy, 2001
- G17DT - a new weapon in the therapeutic armoury for gastrointestinal malignancyExpert Opinion on Biological Therapy, 2001
- Combined Adenovirus-Mediated Nitroreductase Gene Delivery and CB1954 Treatment: A Well-Tolerated Therapy for Established Solid TumorsMolecular Therapy, 2001
- Treatment Options in Hormone-Refractory Prostate CancerDrugs, 2001
- Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regressionGene Therapy, 2000
- Secreted human β-glucuronidase: a novel tool for gene-directed enzyme prodrug therapyGene Therapy, 2000
- Regressions of Established Breast Carcinoma Xenografts by Carboxypeptidase G2 Suicide Gene Therapy and the Prodrug CMDA Are Due to a Bystander EffectHuman Gene Therapy, 2000
- Toward an Enzyme/Prodrug Strategy for Cancer Gene Therapy: Endogenous Activation of Carboxypeptidase A Mutants by the PACE/Furin Family of PropeptidasesHuman Gene Therapy, 1999
- The Bystander Effect of the Nitroreductase/CB 1954 Enzyme/Prodrug System Is Due to a Cell-Permeable MetaboliteHuman Gene Therapy, 1997
- Mustard Prodrugs for Activation by Escherichia coli Nitroreductase in Gene-Directed Enzyme Prodrug TherapyJournal of Medicinal Chemistry, 1997